13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Identification of urinary miRNA biomarkers for detecting cisplatin-induced proximal tubular injury in rats.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Despite increased focus in recent years on urinary microRNA (miRNA) biomarkers in patients with diabetes and chronic kidney diseases, few studies have explored urinary miRNA markers in drug-induced nephrotoxicity. Here, we attempted to identify urinary miRNA markers suitable for use in detecting cisplatin-induced nephrotoxicity in rats. Cisplatin (6mg/kg) was given as a single intraperitoneal injection to male Sprague-Dawley (SD) rats, and urine collected from Days 4 to 5 for 17h under fed or fasted conditions. MiRNAs were identified using TaqMan(®) Rodent microRNA PCR cards, and rats were euthanized 5 days after administration. Levels of 25 miRNAs were significantly increased in the urine of cisplatin-treated rats under both fed and fasted conditions, while the levels of these miRNAs were decreased in either or both the cortex or outer medulla of the kidney. Analysis of time and dose dependency in the urine from rats treated with cisplatin (1, 3, and 6mg/kg) on Days 1, 3, and 7, showed levels of 25 miRNAs were increased in urine and their appearance correlated with the severity of necrosis in the proximal tubules. Four miRNAs (let-7g-5p, miR-93-5p, miR-191a-5p and miR-192-5p) in urine were measured by absolute quantification, and a strong correlation was found between relative and absolute quantification methods. In summary, we identified 25 miRNAs in urine that were able to be used as non-invasive biomarkers for the detection of cisplatin-induced proximal tubular injury in rats. This study is the first step in demonstrating the potential utility of urinary miRNAs in assessing nephrotoxicity. Further study, such as collaborative programs currently underway in the HESI consortium, will clarify the usability of identified miRNA markers in measurement of other nephrotoxicants and injury-site specificity.

          Related collections

          Author and article information

          Journal
          Toxicology
          Toxicology
          1879-3185
          0300-483X
          Oct 3 2014
          : 324
          Affiliations
          [1 ] Drug Safety Research Laboratories, Astellas Pharma Inc, 2-1-6, Kashima, Yodogawa-ku, Osaka 532-8514, Japan. Electronic address: masayuki.kanki@astellas.com.
          [2 ] Drug Safety Research Laboratories, Astellas Pharma Inc, 2-1-6, Kashima, Yodogawa-ku, Osaka 532-8514, Japan.
          [3 ] Astellas Research Technology Co., Ltd, 2-1-6, Kashima, Yodogawa-ku, Osaka 532-8514, Japan.
          Article
          S0300-483X(14)00098-5
          10.1016/j.tox.2014.05.004
          24863737
          16f9fb0a-6589-486e-8511-952b61a21993
          Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
          History

          Biomarker,Cisplatin,Nephrotoxicity,Urine,microRNA
          Biomarker, Cisplatin, Nephrotoxicity, Urine, microRNA

          Comments

          Comment on this article